Pfizer's Sutent Receives FDA Approval To Include New First-Line Advanced Kidney Cancer Data In Label

Fri, 09 Feb 2007 02:00 PM EST

... Pfizer Inc said today that the U.S. Food and Drug Administration (FDA) has approved new labeling of Sutent(R) (sunitinib malate) which includes first-line treatment of advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, based on results of a large Phase 3 trial which showed prolonged progression-free survival. [click link for full article] ...